Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: Does anything work?

Madappa N. Kundranda, Raoul Tibes, Ruben A. Mesa

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it isassociated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylatingagents, and JAK2 inhibition, to try to alter the course of the disease and improve outcomes. This review focuses onthe latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population.

Original languageEnglish (US)
Pages (from-to)78-86
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Volume7
Issue number1
DOIs
StatePublished - Mar 2012

Fingerprint

Acute Myeloid Leukemia
Stem Cell Transplantation
Neoplasms
Blast Crisis
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Therapeutics
Survival
Population

Keywords

  • Acute myelogenous leukemia
  • Acute myeloid leukemia
  • AML
  • Blast phase
  • Essential thrombocythemia
  • JAK2 inhibitors
  • Leukemic transformation
  • Myeloproliferative neoplasm
  • Pathogenesis
  • Polycythemia vera
  • Primary myelofibrosis
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia : Does anything work? / Kundranda, Madappa N.; Tibes, Raoul; Mesa, Ruben A.

In: Current Hematologic Malignancy Reports, Vol. 7, No. 1, 03.2012, p. 78-86.

Research output: Contribution to journalArticle

@article{faccee230da2424e86acaf00950fc655,
title = "Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: Does anything work?",
abstract = "The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it isassociated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylatingagents, and JAK2 inhibition, to try to alter the course of the disease and improve outcomes. This review focuses onthe latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population.",
keywords = "Acute myelogenous leukemia, Acute myeloid leukemia, AML, Blast phase, Essential thrombocythemia, JAK2 inhibitors, Leukemic transformation, Myeloproliferative neoplasm, Pathogenesis, Polycythemia vera, Primary myelofibrosis, Treatment",
author = "Kundranda, {Madappa N.} and Raoul Tibes and Mesa, {Ruben A.}",
year = "2012",
month = "3",
doi = "10.1007/s11899-011-0107-9",
language = "English (US)",
volume = "7",
pages = "78--86",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia

T2 - Does anything work?

AU - Kundranda, Madappa N.

AU - Tibes, Raoul

AU - Mesa, Ruben A.

PY - 2012/3

Y1 - 2012/3

N2 - The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it isassociated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylatingagents, and JAK2 inhibition, to try to alter the course of the disease and improve outcomes. This review focuses onthe latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population.

AB - The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it isassociated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylatingagents, and JAK2 inhibition, to try to alter the course of the disease and improve outcomes. This review focuses onthe latest advances in our understanding of the biology of leukemic transformation and current clinical therapies that are available for this patient population.

KW - Acute myelogenous leukemia

KW - Acute myeloid leukemia

KW - AML

KW - Blast phase

KW - Essential thrombocythemia

KW - JAK2 inhibitors

KW - Leukemic transformation

KW - Myeloproliferative neoplasm

KW - Pathogenesis

KW - Polycythemia vera

KW - Primary myelofibrosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84859238493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859238493&partnerID=8YFLogxK

U2 - 10.1007/s11899-011-0107-9

DO - 10.1007/s11899-011-0107-9

M3 - Article

C2 - 22170483

AN - SCOPUS:84859238493

VL - 7

SP - 78

EP - 86

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -